Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 28 min 36 sec ago

Shire Receives Extension of Market Authorization in Europe for Revestive(R) (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)

Thu, 07/07/2016 - 13:14
This press release is intended for a global audience. First therapy indicated in the EU for use in patients aged one year and above with SBS, a rare gastrointestinal condition ZUG, Switzerland, July 7, 2016 -- (Healthcare Sales & Marketing Network) ...
Biopharmaceuticals, Regulatory
Shire plc, Revestive, teduglutide, Short Bowel Syndrome

NeuroDerm Announces Additions to Management Team

Wed, 07/06/2016 - 16:29
REHOVOT, Israel, July 06, 2016 -- (Healthcare Sales & Marketing Network) -- NeuroDerm Ltd. (NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced the appointments of Tami Yardeni as Chie...
Biopharmaceuticals, Devices, Neurology, Personnel
NeuroDerm, ND0612H, Parkinson’s disease, Levodopa, Carbidopa

FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer

Wed, 07/06/2016 - 16:24
CAMBRIDGE, Mass., July 6, 2016 -- (Healthcare Sales & Marketing Network) -- Merrimack Pharmaceuticals, Inc. (MACK) today announced that the U.S. Food and Drug Administration (FDA) has granted seribantumab, also known as MM-121, Fast Track designation for ...
Biopharmaceuticals, Oncology, FDA
Merrimack Pharmaceuticals, seribantumab, non-small cell lung cancer

Knight and Ember Expand Distribution Partnership

Wed, 07/06/2016 - 15:27
MONTREAL and NEW YORK, July 06, 2016 -- (Healthcare Sales & Marketing Network) -- Knight Therapeutics Inc. (GUD.TO) ("Knight"), a leading Canadian specialty pharmaceutical company, and Ember Therapeutics, Inc. (EMBT) ("Ember"), a New Yo...
Biopharmaceuticals, Distribution
Ember Therapeutics, Knight Therapeutics, Bone Morphogenetic Protein, Migralex

US FDA pathway opens to SCENESSE(R) following Fast Track designation for treatment of EPP

Wed, 07/06/2016 - 15:24
FDA awards Fast Track Designation¹ to expedite review of SCENESSE® in EPP NDA filing allowed on a rolling basis FDA hosting a Scientific Workshop² on EPP to learn more about disease and drug treatment MELBOURNE, Australia and NEW YOR...
Biopharmaceuticals, FDA
Clinuvel Pharmaceuticals, SCENESSE, afamelanotide, erythropoietic protoporphyria

Mylan Launches Generic Fenoglide(R) Tablets

Wed, 07/06/2016 - 15:21
HERTFORDSHIRE, England and PITTSBURGH, July 6, 2016 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Fenofibrate Tablets USP, 40 mg and 120 mg, which is a generic version of Santarus's Fenoglid...
Biopharmaceuticals, Generics, FDA, Product Launch
Mylan, Fenofibrate, Fenoglide, hypercholesterolemia

SI-BONE, Inc. Appoints Tony Recupero Chief Commercial Officer

Tue, 07/05/2016 - 14:47
SAN JOSE, Calif., July 5, 2016 -- (Healthcare Sales & Marketing Network) -- SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System® (iFuse), a triangular-shaped minimally invasive surgical (MIS) device indicated for...
Devices, Orthopaedic, Neurosurgery, Personnel
SI-BONE, iFuse , sacroiliac fusion, degenerative sacroiliitis

Recro Pharma Appoints Michael Celano as Chief Financial Officer

Tue, 07/05/2016 - 14:45
MALVERN, Pa., July 05, 2016 -- (Healthcare Sales & Marketing Network) -- Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced the appointment...
Biopharmaceuticals, Personnel
Recro Pharma, Meloxicam, dexmedetomidine

Eagle Pharmaceuticals Announces Changes to Its Board of Directors; Director, Michael Graves Appointed Chairman

Tue, 07/05/2016 - 14:43
Douglas L. Braunstein and Robert Glenning join the board Hudson Executive Capital LP acquires 6.1% equity interest in Eagle WOODCLIFF LAKE, N.J.--(Healthcare Sales & Marketing Network)--Eagle Pharmaceuticals, Inc. (EGRX) (“Eagle” or the “Company”) ...
Biopharmaceuticals, Personnel
Eagle Pharmaceuticals

Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals

Tue, 07/05/2016 - 13:39
Gains full-rights to Cormorant’s HuMax-IL8 antibody program and lead asset HuMax-IL8 in Phase 1/2 Development Broadens Bristol-Myers Squibb’s oncology pipeline focus on the tumor microenvironment and combination therapy NEW YORK & STOCKHOLM--(Health...
Biopharmaceuticals, Mergers & Acquisitions
Bristol-Myers Squibb, Cormorant Pharmaceuticals, HuMax-IL8

Insys Therapeutics Announces FDA Approval of Syndros(TM)

Tue, 07/05/2016 - 13:32
PHOENIX, July 05, 2016 -- (Healthcare Sales & Marketing Network) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (INSY) today announced that the U.S. Food and Drug Administration (FDA) has approved Insys’ dronabinol oral solution, SyndrosTM, an oral...
Biopharmaceuticals, FDA
Insys Therapeutics, Syndros, dronabinol, cannabinoid

Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. Rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease

Tue, 07/05/2016 - 13:24
OSAKA, Japan and LEUVEN, Belgium, July 5, 2016 -- (Healthcare Sales & Marketing Network) -- Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and TiGenix NV (Euronext Brussels: TIG) ("TiGenix") today announced that the compa...
Biopharmaceuticals, Regenerative Medicine, Licensing
Takeda Pharmaceutical, TiGenix, Crohn's disease

NightBalance Closes EUR 12.5 Million Series B Financing to Support Commercial Rollout in Europe and Enter the U.S. Market with Its Innovative Sleep Apnea Device

Tue, 07/05/2016 - 13:16
Industry veteran Jan Keltjens to be appointed Chairman of the Board of Directors Geoffrey Waters, former President of Respironics International Group, Dirk Kersten of Inkef Capital, and Pieter van der Meer of Gilde Healthcare Partners to join Board of D...
Devices, Venture Capital, Personnel
NightBalance, obstructive sleep apnea, Sleep Position Trainer

Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in Japan

Tue, 07/05/2016 - 13:08
TARRYTOWN, N.Y. and PARIS, July 5, 2016 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authoriz...
Biopharmaceuticals, Cardiology, Regulatory
Regeneron Pharmaceuticals, Sanofi, Praluent, alirocumab

European Commission Approves Extended Indication For Amgen's Kyprolis(R) (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients

Mon, 07/04/2016 - 15:34
Head-to-Head Phase 3 Trial Demonstrated Superiority of Kyprolis and Dexamethasone Over Velcade® (Bortezomib) and Dexamethasone in Patients with Relapsed Multiple Myeloma New Indication Allows Kyprolis to be Used in Combination with Dexamethasone Alo...
Biopharmaceuticals, Oncology, Regulatory
Amgen, Kyprolis, Carfilzomib, Multiple Myeloma

Retina Implant AG Announces Change in Leadership

Mon, 07/04/2016 - 15:28
REUTLINGEN, Germany, July 4, 2016 -- (Healthcare Sales & Marketing Network) -- Following 12 years of successful development at Retina Implant AG, Dr. Walter-G. Wrobel, CEO of the company, has announced his resignation by mutual consent. The resignation wi...
Devices, Ophthalmology, Personnel
Retina Implant AG, Alpha AMS, Subretinal Implant, retinal implant

Patients with Colorectal Cancer Liver Metastases Had Significantly Greater Depth of Tumour Response to SIR-Spheres(R) Y-90 resin microspheres, New SIRFLOX Analysis Shows

Fri, 07/01/2016 - 13:29
BARCELONA, Spain, July 1, 2016 -- (Healthcare Sales & Marketing Network) -- New data presented by Prof. Dr. Volker Heinemann in an oral abstract session at the European Society of Medical Oncology's 18th World Congress on Gastrointestinal Cancer suggest t...
Devices, Oncology
Sirtex Medical, SIR-Spheres, microspheres, SIRFLOX, radiotherapy

Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe

Fri, 07/01/2016 - 13:22
Valeant Receives Upfront Payment & Milestone Payments from AstraZeneca In Exchange for Termination of European Rights to Brodalumab LAVAL, Quebec, July 1, 2016 -- (Healthcare Sales & Marketing Network) -- Valeant Pharmaceuticals International, Inc. (NY...
Biopharmaceuticals, Licensing
Valeant Pharmaceuticals International, AstraZeneca, brodalumab

InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million

Fri, 07/01/2016 - 13:19
BOSTON, MA--(Healthcare Sales & Marketing Network) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announ...
Devices, Interventional
InspireMD, MicroNet, CGuard, MGuard Prime, embolic prevention

Martindale Pharma(R) Announces Extension of Licensing Agreement With Unimedic AB to Include Emergency Care Product Portfolio

Thu, 06/30/2016 - 13:23
Extends Successful Partnership on Adrenaline Ampoules Strengthens Partnership and Leverages Martindale Pharma Manufacturing Capabilities WOOBURN GREEN, England, June 30, 2016 -- (Healthcare Sales & Marketing Network) -- Martindale Pharma, the UK bas...
Biopharmaceuticals, Licensing
Martindale Pharma, Unimedic AB

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong